Pharmacogenomics: Achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems

Current Pharmaceutical Design

Volumn 16, Issue 20, 2010, Pages 2182-2183

  Sanoudou, Despina ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG SPECIFICITY; DRUG TARGETING; EDITORIAL; HEALTH CARE SYSTEM; MOLECULARLY TARGETED THERAPY; PHARMACOGENOMICS; PRIORITY JOURNAL;

DRUG DESIGN; DRUG THERAPY; DRUGS, INVESTIGATIONAL; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT CARE PLANNING; PATIENT SELECTION; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; UNITED STATES;

EID: 77955649695     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791792840     Document Type: Editorial

References (14)

1. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm [cited 2010 April 23].
2. Mountzios G, Sanoudou D and Syrigos K. Clinical Pharmacogenetics in Oncology: the paradigm of molecular targeted therapies. Curr Pharm Des 2010; 16(20): 2184-93.
3. Vafiadaki E, Arvanitis D, Kranias E, et al. Pharmacogenetically tailored treatments for heart disease. Curr Pharm Des 2010; 16(20): 2194-213.
4. Pitychoutis P, Zisaki A, Dalla C, et al. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des 2010; 16(20): 2214-23.
5. Lagoumintzis G, Poulas K and Patrinos G. Genetic databases and their potential in pharmacogenomics. Curr Pharm Des 2010; 16(20): 2224-31.
6. Sato Y, Laird N and Yoshida T. Biostatistic tools in pharmacogenomics - advances, challenges, potential. Curr Pharm Des 2010; 16(20): 2232-40.
7. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=bd34c71e81a32210VgnVCM-100000ed152ca2RCRD&vgnextfmt=default [cited 2010 April 23].
8. http://www.phrma.org/files/attachments/2008%20Profile.pdf [cited 2010 April 23].
9. Wysowski DK and Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363-9.
10. Lazarou J, Pomeranz BH and Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
11. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
12. Vujasinovic T, Zampera A, Jackers P, et al. In silico dynamic molecular interaction networks for the discovery of new therapeutic targets. Curr Pharm Des 2010; 16(20): 2241-51.
13. Poller W and Fechner H. Development of novel cardiovascular therapeutics from small regulatory RNA molecules. Curr Pharm Des 2010; 16(20): 2252-68.
14. Bayet-Robert M, Morvan D, Chollet P, et al. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat 2010; 120: 613-26.